Patents by Inventor Gergana Galabova
Gergana Galabova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230287050Abstract: An antigenic peptide comprises the structure X1-X2-X3-X4-X5-X6-X7-P-X9-X10-X11-X12 and is derived from amino acids 113-124 of alpha synuclein. Ac-cording to the structure: P is proline; X1 is L, K, A or S, wherein L is leucine, K is lysine, A is alanine and S is serine; X2 is E or S, wherein E and S are as defined above; X3 is D, E, K, N, A or S, wherein N is asparagine, D is aspartic acid and D, E, K, A and S are as defined above; X4 is M, A, S, L or K, wherein M is methionine and A, S, L and K are as defined above; X5 is P or A as defined above; X6 is V, A or S, wherein V is valine and A and S are as defined above; X7 is D or S as defined above; X9 is D or A as defined above; X10 is N, S or A, wherein N, S and A are as defined above; X11 is E, A or S, wherein E, A and S are as defined above; X12 is present or not and, if present, is A, K, V, S, or G wherein G is glycine and A, K, V and S are as defined above.Type: ApplicationFiled: August 4, 2021Publication date: September 14, 2023Inventors: Dorian Winter, Günther Staffler, Gergana Galabova, Eva Mihailovska, Petra Gruber, Katja Balazs
-
Publication number: 20210138048Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.Type: ApplicationFiled: January 11, 2021Publication date: May 13, 2021Applicant: AFFIRIS AGInventors: Sylvia BRUNNER, Gergana GALABOVA, Gabriele WINSAUER, Erika BILCIKOVA, Claudia JUNO, Pola LINZMAYER-HIRT, Birgit SCHUH, Guenther STAFFLER
-
Patent number: 10933123Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.Type: GrantFiled: May 21, 2018Date of Patent: March 2, 2021Assignee: AFFIRIS AGInventors: Sylvia Brunner, Gergana Galabova, Gabriele Winsauer, Erika Bilcikova, Claudia Juno, Pola Linzmayer-Hirt, Birgit Schuh, Guenther Staffler
-
Publication number: 20190091306Abstract: Disclosed is a method for vaccination against a self-antigen in a human patient wherein a dose with an effective amount of a self-antigen is administered to the patient to elicit a primary immune response, characterised in that the patient is subjected to a boost administration of said self-antigen, wherein the amount of the self-antigen in the dose for the boost administration is higher than the amount of the self-antigen in the dose used in the administration for the primary immune response.Type: ApplicationFiled: November 2, 2016Publication date: March 28, 2019Applicant: AFFIRIS AGInventors: Gergana GALABOVA, Sabine SCHMIDHUBER, Achim SCHNEEBERGER, Arne VON BONIN, Dorian WINTER, Jana ZIMMERMANN
-
Publication number: 20180289781Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.Type: ApplicationFiled: May 21, 2018Publication date: October 11, 2018Applicant: AFFIRIS AGInventors: Sylvia Brunner, Gergana Galabova, Gabriele Winsauer, Erika Bilcikova, Claudia Juno, Pola Linzmayer-Hirt, Birgit Schuh, Guenther Staffler
-
Patent number: 10004791Abstract: The present invention relates to a vaccine capable to induce production of antibodies directed to PCSK9 in vivo.Type: GrantFiled: February 23, 2015Date of Patent: June 26, 2018Assignee: AFFIRIS AGInventors: Gergana Galabova, Guenther Staffler, Sylvia Brunner, Gabriele Winsauer, Andreas Mairhofer, Claudia Juno
-
Patent number: 9999659Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.Type: GrantFiled: December 2, 2016Date of Patent: June 19, 2018Assignee: AFFIRIS AGInventors: Sylvia Brunner, Gergana Galabova, Gabriele Winsauer, Erika Bilcikova, Claudia Juno, Pola Linzmayer-Hirt, Birgit Schuh, Guenther Staffler
-
Patent number: 9669079Abstract: The present invention relates to a immunogen comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID NO:9).Type: GrantFiled: October 23, 2015Date of Patent: June 6, 2017Assignee: AFFIRIS AGInventors: Sylvia Brunner, Gergana Galabova, Bettina Wanko, Markus Windwarder, Gabriele Winsauer, Guenther Staffler, Claudia Juno
-
Publication number: 20170112908Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.Type: ApplicationFiled: December 2, 2016Publication date: April 27, 2017Applicant: AFFIRIS ABInventors: Sylvia BRUNNER, Gergana Galabova, Gabriele Winsauer, Erika Bilcikova, Claudia Juno, Pola Linzmayer-Hirt, Birgit Schuh, Guenther Staffler
-
Publication number: 20170065689Abstract: The present invention relates to a vaccine capable to induce production of antibodies directed to PCSK9 in vivo.Type: ApplicationFiled: February 23, 2015Publication date: March 9, 2017Applicant: AFFIRIS AGInventors: Gergana GALABOVA, Guenther STAFFLER, Sylvia BRUNNER, Gabriele WINSAUER, Andreas MAIRHOFER, Claudia Juno
-
Patent number: 9533030Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.Type: GrantFiled: August 28, 2013Date of Patent: January 3, 2017Assignee: AFFIRIS AGInventors: Sylvia Brunner, Gergana Galabova, Gabriele Winsauer, Erika Bilcikova, Claudia Juno, Pola Linzmayer-Hirt, Birgit Schuh, Guenther Staffler
-
Publication number: 20160106822Abstract: The present invention relates to a immunogen comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID NO:9).Type: ApplicationFiled: October 23, 2015Publication date: April 21, 2016Applicant: Affiris AGInventors: Sylvia BRUNNER, Gergana Galabova, Bettina Wanko, Markus Windwarder, Gabriele Winsauer, Guenther Staffler, Claudia Juno
-
Patent number: 9220762Abstract: A vaccine or immunogenic composition comprising at least two fragments of proprotein convertase subtilisin/kexin type 9 (PCSK9) where one fragment contains at least 9 consecutive residues of residues 153 to 165 of PCSK9 and the other fragment contains at least 9 consecutive residues 209 to 222 of the PCSK9 (SEQ ID NO:9). Methods of treatment for hyperlipidemia, hypercholesterolemia, and atherosclerosis involving administering this vaccine.Type: GrantFiled: September 13, 2012Date of Patent: December 29, 2015Assignee: AFFIRIS AGInventors: Sylvia Brunner, Gergana Galabova, Bettina Wanko, Markus Windwarder, Gabriele Winsauer, Guenther Staffler, Claudia Juno
-
Publication number: 20150306191Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.Type: ApplicationFiled: August 28, 2013Publication date: October 29, 2015Applicant: AFFIRIS AGInventors: Sylvia BRUNNER, Gergana GALABOVA, Gabriele WINSAUER, Erika BILCIKOVA, Claudia JUNO, Pola LINZMAYER-HIRT, Birgit SCHUH, Guenther STAFFLER
-
Publication number: 20150071951Abstract: The present invention relates to a vaccine comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein said at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID No. 9).Type: ApplicationFiled: September 13, 2012Publication date: March 12, 2015Applicant: AFFIRIS AGInventors: Sylvia Brunner, Gergana Galabova, Bettina Wanko, Markus Windwarder, Gabriele Winsauer, Guenther Staffler, Claudia Juno